Evaluation of Pseudomonas aeruginosa staphylolysin (LasA protease) in the treatment of methicillin-resistant Staphylococcus aureus endophthalmitis in a rat model

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 247, Issue 7, 2009, Pages 913-917

  Barequet, Irina S ^a,d   Habot Wilner, Zohar ^a   Mann, Oran ^b   Safrin, Mary ^a   Ohman, Dennis E ^c   Kessler, Efrat ^a   Rosner, Mordechai ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

Endophthalmitis; LasA protease; Rat model; Staphylococcus aureus; Staphylolysin

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL ENZYME; STAPHYLOLYSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; HISTOPATHOLOGY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RAT; TOXICITY TESTING;

ANIMALS; COLONY COUNT, MICROBIAL; DRUG ADMINISTRATION SCHEDULE; ENDOPHTHALMITIS; ENDOTOXINS; INJECTIONS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PSEUDOMONAS AERUGINOSA; RATS; RATS, WISTAR; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VITREOUS BODY;

EID: 67349162642     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-009-1061-2     Document Type: Article

References (22)

1. Affedlt JC, Flynn HW, Forster RK, Mandelbaum S, Clarkson JG, Jarus GD (1987) Microbial endophthalmitis resulting from ocular trauma. Ophthalmol 94:407-413
2. Han DP, Wisniewski SR, Wilson LA, Barza M, Vine AK, Doft BH, Kelsey SF (1996) Spectrum and susceptibilities of microbiologic isolates in the endophthalmitis vitrectomy study. Am J Ophthalmol 122:1-17
3. Mao LK, Flynn HW, Miller D, Pflugfelder SC (1993) Endophthalmitis caused by Staphylococcus aureus. Am J Ophthalmol 116:584-589
4. Alexandrakis G, Alfonso EC, Miller D (2000) Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmol 107:1497-1502, doi: 10.1016/S0161-6420(00)00179-2
5. Daum RS, Seal JB (2001) Evolving antimicrobial chemotherapy for Staphylococcus aureus infections: Our backs to the wall. Crit Care Med 29(Suppl.):N92-N96, doi: 10.1097/00003246-200104001-00007
6. Hiramatsu K (1998) The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Ann J Med 104:7S-10S
7. Srinivasan A, Dick JD, Perl TM (2002) Vancomycin resistance in Staphylococci. Clin Microbiol Rev 15:430-438, doi: 10.1128/ CMR.15.3.430-438.2002
8. Walsh TR, Howe RA (2002) The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu Rev Microbiol 56:657-675, doi: 10.1146/annurev.micro.56.012302.160806
9. Dajcs JJ, Hume EB, Moreau JM, Caballero AR, Cannon BM, O'Callaghan RJ (2000) Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit. Invest Ophthalmol Vis Sci 41:1432-1437
10. Dajcs JJ, Thibodeaux BA, Hume EB, Zheng X, Sloop GD, O'Callaghan RJ (2001) Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus endophthalmitis in the rabbit. Curr Eye Res 22:451-457, doi: 10.1076/ceyr.22.6.451.5486
11. Dajcs JJ, Thibodeaux BA, Girgis DO, Shaffer MD, Delvisco SM, O'Callaghan RJ (2002) Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit. Invest Ophthalmol Vis Sci 43:3712-3716
12. Dixon RE, Goodman JS, Koenig MG (1968) Lysostaphin; an enzymatic approach to staphylococcal disease. III. Combined lysostaphin-methicillin in therapy of established staphylococcal abscesses in mice. Yale J Biol Med 41:62-68
13. Harrison EF, Cropp CB (1967) Therapeutic activity of lysostaphin in experimental staphylococcal infections. Can J Microbiol 13:93-97
14. Schindler CA, Schuhardt VT (1964) Lysostaphin: A new bacteriolytic agent for Staphylococcus. Proc Natl Acad Sci USA 51:414-421, doi: 10.1073/ pnas.51.3.414
15. Zygmunt W, Tavormina PA (1972) Lysostaphin: Model for a specific enzymatic approach to infectious disease. Prog Drug Res 16:309-333
16. Barequet IS, Ben Simon GJ, Safrin M, Ohman DE, Kessler E (2004) Pseudomonas aeruginosa Staphylolysin protease in treatment of experimental staphylococcal keratitis. Antimicrob Agents Chemother 48:1681-1687, doi: 10.1128/AAC.48.5.1681-1687.2004
17. Kessler E, Safrin M, Olson JC, Ohman DE (1993) Secreted Staphylolysin protease of Pseudomonas aeruginosa is a staphylolytic protease. J Biol Chem 268:7503-7508
18. Mansito TB, Falcon MA, Moreno J, Carnicero A, Gutierrez-Navarro AM (1987) Effects of staphylolytic enzymes from Pseudomonas aeruginosa on the growth and ultra structure of Staphylococcus aureus. Microbios 49:55-64
19. Perestelo FR, Blanco MT, Gutierre-Navarro AM, Falcon MA (1985) Growth inhibition of Staphylococcus aureus by a staphylolytic enzyme from Pseudomonas aeruginosa. Microbios Lett 30:85-94
20. Berkowitz BA, Lukaszew RA, Mullins CM, Penn JS (1998) Impaired hyaloidal circulation function and uncoordinated ocular growth patterns in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci 39:391-396
21. McCormick CC, Dajcs JJ, Reed JM, Marquart ME, O'Callaghan RJ (2006) The effectiveness of lysostaphin therapy for experimental coagulase-negative Staphylococcus endophthalmitis. Curr Eye Res 31:225-230, doi: 10.1080/ 02713680500536753
22. Climo MW, Ehlert K, Archer GL (2001) Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 45:1431-1437, doi: 10.1128/ AAC.45.5.1431-1437.2001